BioCentury
ARTICLE | Clinical News

AG-221: Phase Ib/II started

April 11, 2016 7:00 AM UTC

Celgene began an open-label, international Phase Ib/II trial to evaluate once-daily oral AG-221 or AG-120 with subcutaneous Vidaza azacitidine given for the first 7 days of each 28-day cycle in up to 150 patients who are not eligible for intensive chemotherapy. In the dose-escalation, Phase Ib portion, patients with an IDH1 mutation will receive AG-120 at an initial dose of 500 mg plus Vidaza and patients with an IDH2 mutation will receive AG-221 at an initial dose of 100 mg plus Vidaza. The Phase II portion will compare the combinations vs. Vidaza alone. ...